ALIVUSNSEQ1 FY24July 21, 2023

Alivus Life Sciences Limited

2,239words
1turns
0analyst exchanges
0executives
Key numbers — 40 extracted
rs,
July 21, 2023 To, Dy. General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai – 400 001 To, The Manager – Listing, National Stock Exchange of Indi
18.1%
ly situation will act as catalyst for growth in the coming quarters.” (I N ₹ M I LLI O N S ) 5,785 18.1% REVENUE YoY (6.9%) QoQ (I N ₹ M I LLI O N S ) 1,950 24.8% EBITDA YoY (6.8%) QoQ • GLS registe
6.9%
as catalyst for growth in the coming quarters.” (I N ₹ M I LLI O N S ) 5,785 18.1% REVENUE YoY (6.9%) QoQ (I N ₹ M I LLI O N S ) 1,950 24.8% EBITDA YoY (6.8%) QoQ • GLS registered a revenue from o
24.8%
arters.” (I N ₹ M I LLI O N S ) 5,785 18.1% REVENUE YoY (6.9%) QoQ (I N ₹ M I LLI O N S ) 1,950 24.8% EBITDA YoY (6.8%) QoQ • GLS registered a revenue from operations of ₹ 5,785 Mn for Q1 FY24, reco
6.8%
LLI O N S ) 5,785 18.1% REVENUE YoY (6.9%) QoQ (I N ₹ M I LLI O N S ) 1,950 24.8% EBITDA YoY (6.8%) QoQ • GLS registered a revenue from operations of ₹ 5,785 Mn for Q1 FY24, recording a strong gr
₹ 5,785
M I LLI O N S ) 1,950 24.8% EBITDA YoY (6.8%) QoQ • GLS registered a revenue from operations of ₹ 5,785 Mn for Q1 FY24, recording a strong growth of 18.1% YoY and a decline of 6.9% compared to high base
17.8%
External business and GPL business both continue to deliver strong growth momentum growing around 17.8% YoY and 18.6% YoY respectively • CDMO business has grown strongly by 91% on YoY basis • Gross Mar
18.6%
ness and GPL business both continue to deliver strong growth momentum growing around 17.8% YoY and 18.6% YoY respectively • CDMO business has grown strongly by 91% on YoY basis • Gross Margins improved
91%
omentum growing around 17.8% YoY and 18.6% YoY respectively • CDMO business has grown strongly by 91% on YoY basis • Gross Margins improved strongly in Q1 FY24 trending at 57.1%, up 220 bps QoQ and 38
57.1%
ss has grown strongly by 91% on YoY basis • Gross Margins improved strongly in Q1 FY24 trending at 57.1%, up 220 bps QoQ and 380 (I N ₹ M I LLI O N S ) 1,355 24.6% PAT YoY (7.5%) QoQ • bps YoY; driv
220 bps
wn strongly by 91% on YoY basis • Gross Margins improved strongly in Q1 FY24 trending at 57.1%, up 220 bps QoQ and 380 (I N ₹ M I LLI O N S ) 1,355 24.6% PAT YoY (7.5%) QoQ • bps YoY; driven by lower
24.6%
proved strongly in Q1 FY24 trending at 57.1%, up 220 bps QoQ and 380 (I N ₹ M I LLI O N S ) 1,355 24.6% PAT YoY (7.5%) QoQ • bps YoY; driven by lower input costs and better product mix EBITDA margin
Speaking time
REGISTERED OFFICE
1
Advertisement
Opening remarks
REGISTERED OFFICE
T: 91 22 68297979 4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai, 400 099, India. Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur - 413 213, India. CIN: U74900PN2011PLC139963 Website: www.glenmarklifesciences.com 19
Advertisement
← All transcriptsALIVUS stock page →